Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 04/01/24
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of DirectorsGlobeNewsWire • 02/13/24
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to MarketGlobeNewsWire • 01/29/24
Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearingMarket Watch • 12/28/23
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)GlobeNewsWire • 12/01/23
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 11/13/23
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDGlobeNewsWire • 09/11/23
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a PremiumGlobeNewsWire • 09/08/23
Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD PatientsBusiness Wire • 09/06/23
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023GlobeNewsWire • 09/05/23
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business UpdateGlobeNewsWire • 08/14/23
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and AugustGlobeNewsWire • 06/29/23
Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-VestGlobeNewsWire • 06/14/23